by Team Small News | Jan 29, 2026 | Biocon, Pharma
S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to ‘BB+’ from ‘BB’. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament... by Team Small News | Jan 19, 2026 | Biocon, Pharma
Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company’s biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role.... by Team Small News | Jan 7, 2026 | Biocon, Pharma
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab/Hyaluronidase, Nivolumab, and... by Team Small News | Jan 4, 2026 | Biocon, Pharma
A 26-year-old employee of Biocon, a biopharmaceutical company, jumped to his death from the 5th floor of the company’s office building in Bengaluru, India. The incident occurred on a recent day, and the police are currently investigating the circumstances...